NextTrip Stock Price, News & Analysis

NextTrip has unveiled FlexPay, a proprietary technology for their travel booking site, which introduces flexible payment options. FlexPay allows customers to pay for accommodations over time through interest-free installments and does not require credit checks. This feature aims to capitalize on the growing trend of 'buy now, pay later' services, which represented 4% of 2021 e-commerce transactions in Canada and the US and is expected to grow to 9% by 2025. FlexPay is integrated into the booking process and will be used in social media travel campaigns and direct-to-consumer marketing to drive sales and conversion rates. NextTrip anticipates that FlexPay will make travel more affordable and flexible, particularly appealing to younger travelers, and enhance marketing efforts throughout the year.

NextTrip, a travel technology company, has received a notification from Nasdaq indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its annual report on Form 10-K for the fiscal year ending February 29, 2024. The company now has 60 days to submit a compliance plan to Nasdaq. If accepted, NextTrip may have until December 10, 2024, to meet the filing requirements. Further details are available in the company's Form 8-K filed with the SEC.

Summary not available.

Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first batch of synthetic Bryostatin under an exclusive licensing agreement with Stanford University. This development will enable the company to expand its research and conduct trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's disease. The synthetic supply addresses the need for increased availability, crucial for the development of orally deliverable compounds. The company aims to complement ongoing Phase 2 trials in Alzheimer's Disease with additional studies utilizing the new supply.

Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first synthetic Bryostatin batch, obtained through an exclusive licensing agreement with Stanford University. This development marks a significant milestone, allowing the company to expand its research initiatives, particularly for an orally deliverable compound. The increased supply will facilitate new clinical trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's. Synaptogenix's existing studies include Bryostatin-1, which has a notable safety profile from prior cancer research.

Neurotrope and Metuchen Pharmaceuticals have completed their merger, creating a new public holding company, Petros Pharmaceuticals, trading under the symbol PTPI. Neurotrope shareholders will own approximately 49% and Metuchen shareholders 51% of Petros. This merger includes a spin-off of Neurotrope's existing assets and liabilities. Petros aims to enhance the commercialization of its lead product, Stendra®, an FDA-approved erectile dysfunction treatment, while exploring its potential shift to over-the-counter status. The merger intends to create long-term value for stakeholders.

Neurotrope, Inc. (NASDAQ: NTRP) announced its Board of Directors approved the spin-off of its subsidiary, Neurotrope Bioscience, Inc. (NBI). Shareholders of record on November 30, 2020, will receive one share of NBI for every five shares of Neurotrope held on December 7, 2020. This follows a planned merger with Metuchen Pharmaceuticals, forming a new company named Petros Pharmaceuticals, Inc. The distribution is taxable and subject to specific conditions, including shareholder approval of the merger set for November 25, 2020.

Neurotrope (Nasdaq: NTRP) has initiated a long-term Phase 2 clinical study of Bryostatin-1 for Alzheimer's disease, dosing its first patient. Supported by a $2.7 million NIH grant, this study aims to enroll about 100 patients over six months, evaluating cognitive benefits in the absence of Namenda. Previous pilot trials indicated Bryostatin-1 was well tolerated and showed promising cognitive improvements. The trial represents a key milestone for Neurotrope as it seeks to advance treatment options for Alzheimer's while planning a merger with Metuchen Pharmaceuticals.

Neurotrope has amended its merger agreement with Metuchen Pharmaceuticals, increasing Neurotrope stockholders' ownership in the new company, Petros Pharmaceuticals, to 49%. Originally, it was set at 22.5%. The merger will spin out Neurotrope's lead asset, Bryostatin-1, into a separate entity while Petros focuses on its core products: Stendra® and H-100, a treatment for Peyronie's disease. Petros aims to enhance Stendra's market presence and explore converting it to over-the-counter availability. The transaction is expected to close in the fourth quarter of 2020.